TNFα stimulates NKG2D-mediated lytic activity of acute myeloid leukemic cells

Leukemia

Volumn 19, Issue 12, 2005, Pages 2206-2214

  Guilloton, F ^a   de Thonel, A ^a,b   Jean, C ^a   Demur, C ^a   Mansat De Mas, V ^a   Laurent, G ^a   Quillet Mary, Anne ^a  

^a CHU PURPAN   (France)

^b TURKU CENTRE FOR BIOTECHNOLOGY   (Finland)

Author keywords

AML cells; MDS; NKG2D; TNF

Indexed keywords

ADAPTOR PROTEIN; CD34 ANTIGEN; GRANZYME B; LIGAND; NATURAL KILLER CELL RECEPTOR NKG2D; PERFORIN; TUMOR NECROSIS FACTOR ALPHA; GRANZYME; GZMB PROTEIN, HUMAN; IMMUNOGLOBULIN RECEPTOR; MEMBRANE PROTEIN; NATURAL KILLER CELL ACTIVATING RECEPTORS; PORE FORMING CYTOTOXIC PROTEIN; SERINE PROTEINASE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL MEDIATED CYTOTOXICITY; CLINICAL ARTICLE; COLONY FORMING UNIT GM; CONTROLLED STUDY; CYTOLYSIS; ENZYME ACTIVATION; FLOW CYTOMETRY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; LEUKEMIA CELL; MYELODYSPLASTIC SYNDROME; MYELOID PROGENITOR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; ACUTE DISEASE; COCULTURE; CYTOLOGY; CYTOTOXICITY; GENETICS; IMMUNOLOGY; MYELOID LEUKEMIA; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; UPREGULATION;

ACUTE DISEASE; CELL LINE, TUMOR; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; GRANZYMES; HEMATOPOIESIS; HUMANS; LEUKEMIA, MYELOID; MEMBRANE GLYCOPROTEINS; MYELOID PROGENITOR CELLS; PORE FORMING CYTOTOXIC PROTEINS; RECEPTORS, IMMUNOLOGIC; SERINE ENDOPEPTIDASES; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 28544451339     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2403952     Document Type: Article

References (57)

1. Yoshida Y. Hypothesis: Apoptosis may be the mechanism responsible for the premature intramedullary cell death in the myelodysplastic syndrome. Leukemia 1993; 7: 144-146.
2. Raza A, Gezer S, Mundle S, Gao XZ, Alvi S, Borok R et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 1995; 86: 268-276.
3. Bryder D, Ramsfjell V, Dybeda I, Theilgaard-Monch K, Hogerkorp CM, Adolfsson J et al. Self-renewal of multipotent long-term repopulating hematopoietic stem cells is negatively regulated by Fas and tumor necrosis factor receptor activation. J Exp Med 2001; 194: 941-952.
4. Raza A, Gregory SA, Preisler HD. The myelodysplastic syndromes in 1996: complex stem cell disorders confounded by dual actions of cytokines. Leuk Res 1996; 20: 881-890.
5. Raza A, Mundle S, Shetty V, Alvi S, Chopra H, Span L et al. Novel insights into the biology of myelodysplastic syndromes: Excessive apoptosis and the role of cytokines. Int J Hematol 1996; 63: 265-278.
6. Kitagawa M, Saito I, Kuwata T, Yoshida S, Yamaguchi S, Takahashi M et al. Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes. Leukemia 1997; 11: 2049-2054.
7. Plo I, Lautier D, Levade T, Sekouri H, Jaffrezou JP, Laurent G et al. Phosphatidylcholine-specific phospholipase C and phospholipase D are respectively implicated in mitogen-activated protein kinase and nuclear factor kappaB activation in tumour-necrosis-factor-alpha-treated immature acute-myeloid-leukaemia cells. Biochem J 2000; 351: 459-467.
8. Tien HF, Wang CH. CD7 positive hematopoietic progenitors and acute myeloid leukemia and other minimally differentiated leukemia. Leuk Lymphoma 1998; 31: 93-98.
9. Graf M, Reif S, Hecht K, Pelka-Fleischer R, Kroell T, Pfister K et al. High expression of costimulatory molecules correlates with low relapse-free survival probability in acute myeloid leukemia (AML). Ann Hematol 2005; 84: 287-297.
10. Raspadori D, Damiani D, Michieli M, Stocchi R, Gentili S, Gozzetti A et al. CD56 and PGP expression in acute myeloid leukemia: Impact on clinical outcome. Haematologica 2002; 87: 1135-1140.
11. Sconocchia G, Fujiwara H, Rezvani K, Keyvanfar K, El Ouriaghli F, Grube M et al. G-CSF-mobilized CD34+ cells cultured in interleukin-2 and stem cell factor generate a phenotypically novel monocyte. J Leukoc Biol 2004; 76: 1214-1219.
12. Kojima H, Bai A, Mukai HY, Hori M, Komeno T, Hasegawa Y et al. Chronic myelomonocytic leukemia derived from a possible common progenitor of monocytes and natural killer cells. Leuk Lymphoma 2000; 37: 617-621.
13. Morita Y, Matsuda M, Hanamoto H, Shimada T, Tatsumi Y, Maeda Y et al. A perforin/granzyme-positive MDS-derived T cell line, K2-MDS, induces apoptosis in CD34+ cells through the fractalkine-CX3CR1 system. Clin Immunol 2004; 113: 109-116.
14. Bruno AP, Lautier D, d'Orgeix AT, Laurent G, Quillet-Mary A. Acute myeloblastic leukemic cells acquire cellular cytotoxicity under genotoxic stress: Implication of granzyme B and perforin. Blood 2000; 96: 1914-1920.
15. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001; 19: 197-223.
16. Pende D, Cantoni C, Rivera P, Vitale M, Castriconi R, Marcenaro S et al. Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin. Eur J Immunol 2001; 31: 1076-1086.
17. Vivier E, Tomasello E, Paul P. Lymphocyte activation via NKG2D: Towards a new paradigm in immune recognition? Curr Opin Immunol 2002; 14: 306-311.
18. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999; 285: 727-729.
19. Groh V, Bruhl A, El-Gabalawy H, Nelson JL, Spies T. Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. Proc Natl Acad Sci USA 2003; 100: 9452-9457.
20. Andre P, Castriconi R, Espeli M, Anfossi N, Juarez T, Hue S et al. Comparative analysis of human NK cell activation induced by NKG2D and natural cytotoxicity receptors. Eur J Immunol 2004; 34: 961-971.
21. Cao W, He W. UL16 binding proteins. Immunobiology 2004; 209: 283-290.
22. Groh V, Bahram S, Bauer S, Herman A, Beauchamp M, Spies T. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci USA 1996; 93: 12445-12450.
23. Wu J, Song Y, Bakker AB, Bauer S, Spies T, Lanier LL et al. An activating immunoreceptor complex formed by NKG2D and DAP10. Science 1999; 285: 730-732.
24. Arnon TI, Lev M, Katz G, Chernobrov Y, Porgador A, Mandelboim O. Recognition of viral hemagglutinins by NKp44 but not by NKp30. Eur J Immunol 2001; 31: 2680-2689.
25. Mandelboim O, Lieberman N, Lev M, Paul L, Arnon TI, Bushkin Y et al. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 2001; 409: 1055-1060.
26. Mandelboim O, Porgador A. NKp46. Int J Biochem Cell Biol 2001; 33: 1147-1150.
27. Bloushtain N, Qimron U, Bar-Ilan A, Hershkovitz O, Gazit R, Fima E et al. Membrane-associated heparan sulfate proteoglycans are involved in the recognition of cellular targets by NKp30 and NKp46. J Immunol 2004; 173: 2392-2401.
28. Nowbakht P, Ionescu MC, Rohner A, Kalberer CP, Rossy E, Mori L et al. Ligands for natural killer cell activating receptors are expressed upon maturation of normal myelomonocytic cells but are low in acute myeloid leukemias. Blood 2005, (E-pub ahead of print).
29. Augugliaro R, Parolini S, Castriconi R, Marcenaro E, Cantoni C, Nanni M et al. Selective cross-talk among natural cytotoxicity receptors in human natural killer cells. Eur J Immunol 2003; 33: 1235-1241.
30. Quentmeier H, Zaborski M, Drexler HG. The human bladder carcinoma cell line 5637 constitutively secretes functional cytokines. Leuk Res 1997; 21: 343-350.
31. Decker T, Lohmann-Matthes ML. A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J Immunol Methods 1988; 115: 61-69.
32. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 402-408.
33. Kim KM, Lee K, Hong YS, Park HY. Fas-mediated apoptosis and expression of related genes in human malignant hematopoietic cells. Exp Mol Med 2000; 32: 246-254.
34. Beran M, Andersson BS, Kelleher P, Whalen K, McCredie K, Gutterman J. Diversity of the effect of recombinant tumor necrosis factors alpha and beta on human myelogenous leukemia cell lines. Blood 1987; 69: 721-726.
35. Odake S, Kam CM, Narasimhan L, Poe M, Blake JT, Krahenbuhl O et al. Human and murine cytotoxic T lymphocyte serine proteases: Subsite mapping with peptide thioester substrates and inhibition of enzyme activity and cytolysis by isocoumarins. Biochemistry 1991; 30: 2217-2227.
36. Hudig D, Allison NJ, Pickett TM, Winkler U, Kam CM, Powers JC. The function of lymphocyte proteases. Inhibition and restoration of granule-mediated lysis with isocoumarin serine protease inhibitors. J Immunol 1991; 147: 1360-1368.
37. Hampson IN, Cross MA, Heyworth CM, Fairbairn L, Spooncer E, Cowling GJ et al. Expression and downregulation of cytotoxic cell protease 1 or Granzyme 'B' transcripts during myeloid differentiation of interleukin-3-dependent murine stem cell lines. Blood 1992; 80: 3097-3105.
38. Berthou C, Marolleau JP, Lafaurie C, Soulie A, Dal Cortivo L, Bourge JF et al. Granzyme B and perforin lytic proteins are expressed in CD34+ peripheral blood progenitor cells mobilized by chemotherapy and granulocyte colony-stimulating factor. Blood 1995; 86: 3500-3506.
39. Rissoan MC, Duhen T, Bridon JM, Bendriss-Vermare N, Peronne C, de Saint Vis B et al. Subtractive hybridization reveals the expression of immunoglobulin-like transcript 7, Eph-B1, granzyme B, and 3 novel transcripts in human plasmacytoid dendritic cells. Blood 2002; 100: 3295-3303.
40. Wagner C, Iking-Konert C, Denefleh B, Stegmaier S, Hug F, Hansch CM. Granzyme B and perforin: Constitutive expression in human polymorphonuclear neutrophils. Blood 2004; 103: 1099-1104.
41. Hu SX, Wang S, Wang JP, Mills GB, Zhou Y, Xu HJ. Expression of endogenous granzyme B in a subset of human primary breast carcinomas. Br J Cancer 2003; 89: 135-139.
42. Zhou YJ, Xiong YX, Li CP, Shi D. Suppression of local immune response by GrB expression in gastric cancer cells. Chin Med J 2004; 117: 1573-1575.
43. Berthou C, Michel L, Soulie A, Jean-Louis F, Flageul B, Dubertret L et al. Acquisition of granzyme B and Fas ligand proteins by human keratinocytes contributes to epidermal cell defense. J Immunol 1997; 159: 5293-5300.
44. Sasson R, Amsterdam A. Pleiotropic anti-apoptotic activity of glucocorticoids in ovarian follicular cells. Biochem Pharmacol 2003; 66: 1393-1401.
45. Gao XZ, Bi S, Copra H, Devemy E, Venugopal P, Li B et al. Cytokine gene activity in AML cells in vivo in patients. Leuk Res 1998; 22: 429-438.
46. Kurzrock R, Kantarjian H, Wetzler M, Estrov Z, Estey E, Troutman-Worden K et al. Ubiquitous expression of cytokines in diverse leukemias of lymphoid and myeloid lineage. Exp Hematol 1993; 21: 80-85.
47. Oster W, Cicco NA, Klein H, Hirano T, Kishimoto T, Lindemann A et al. Participation of the cytokines interleukin 6, tumor necrosis factor-alpha, and interleukin 1-beta secreted by acute myelogenous leukemia blasts in autocrine and paracrine leukemia growth control. J Clin Invest 1989; 84: 451-457.
48. Ostermann H, Rothenburger M, Mesters RM, van de Loo J, Kienast J. Cytokine response to infection in patients with acute myelogenous leukaemia following intensive chemotherapy. Br J Haematol 1994; 88: 332-337.
49. Dybedal I, Bryder D, Fossum A, Rusten LS, Jacobsen SE. Tumor necrosis factor (TNF)-mediated activation of the p55 TNF receptor negatively regulates maintenance of cycling reconstituting human hematopoietic stem cells. Blood 2001; 98: 1782-1791.
50. Maguer-Satta V, Oostendorp R, Reid D, Eaves CJ. Evidence that ceramide mediates the ability of tumor necrosis factor to modulate primitive human hematopoietic cell fates. Blood 2000; 96: 4118-4123.
51. Motyka B, Korbutt G, Pinkoski MJ, Heibein JA, Caputo A, Hobman M et al. Mannose 6-phosphate/insulin-like growth factor II receptor is a death receptor for granzyme B during cytotoxic T cell-induced apoptosis. Cell 2000; 103: 491-500.
52. Lehmann C, Zeis M, Schmitz N, Uharek L. Impaired binding of perforin on the surface of tumor cells is a cause of target cell resistance against cytotoxic effector cells. Blood 2000; 96: 594-600.
53. Sun J, Bird CH, Sutton V, McDonald L, Coughlin PB, De Jong TA et al. A cytosolic granzyme B inhibitor related to the viral apoptotic regulator cytokine response modifier A is present in cytotoxic lymphocytes. J Biol Chem 1996; 271: 27802-27809.
54. Hirst CE, Buzza MS, Bird CH, Warren HS, Cameron PU, Zhang M et al. The intracellular granzyme B inhibitor, proteinase inhibitor 9, is up-regulated during accessory cell maturation and effector cell degranulation, and its overexpression enhances CTL potency. J Immunol 2003; 170: 805-815.
55. Perez OD, Mitchell D, Jager GC, Nolan GP. LFA-1 signaling through p44/42 is coupled to perforin degranulation in CD56+CD8+ natural killer cells. Blood 2004; 104: 1083-1093.
56. Allcock RJ, Barrow AD, Forbes S, Beck S, Trowsdale J. The human TREM gene cluster at 6p21.1 encodes both activating and inhibitory single IgV domain receptors and includes NKp44. Eur J Immunol 2003; 33: 567-577.
57. Biassoni R, Cantoni C, Pende D, Sivori S, Parolini S, Vitale M et al. Human natural killer cell receptors and co-receptors. Immunol Rev 2001; 181: 203-214.